These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 19320940

  • 1. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
    Böhm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck K, Vales A, Gleixner KV, Pickl WF, Sperr WR, Valent P.
    Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
    [Abstract] [Full Text] [Related]

  • 2. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
    Frost P, Shi Y, Hoang B, Lichtenstein A.
    Oncogene; 2007 Apr 05; 26(16):2255-62. PubMed ID: 17016437
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov 05; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
    Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY.
    Pathol Int; 2009 Jan 05; 59(1):19-27. PubMed ID: 19121088
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.
    Sillaber C, Mayerhofer M, Böhm A, Vales A, Gruze A, Aichberger KJ, Esterbauer H, Pfeilstöcker M, Sperr WR, Pickl WF, Haas OA, Valent P.
    Eur J Clin Invest; 2008 Jan 05; 38(1):43-52. PubMed ID: 18173550
    [Abstract] [Full Text] [Related]

  • 6. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 05; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 7. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.
    Cancer Res; 2006 Jun 01; 66(11):5549-54. PubMed ID: 16740688
    [Abstract] [Full Text] [Related]

  • 8. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels.
    Glenjen NI, Hatfield K, Bruserud Ø.
    Eur J Haematol; 2005 Jan 01; 74(1):24-34. PubMed ID: 15613103
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
    Imai N, Shikami M, Miwa H, Suganuma K, Hiramatsu A, Watarai M, Satoh A, Itoh M, Imamura A, Mihara H, Nitta M.
    Br J Haematol; 2006 Dec 01; 135(5):673-82. PubMed ID: 17107349
    [Abstract] [Full Text] [Related]

  • 11. [Vascular endothelial growth factor antisense oligodeoxynucleotide enhance drug-sensitivity of myeloid leukemia cells to homoharringtonine].
    Fei J, Zhang H.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):27-30. PubMed ID: 15946505
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.
    Brain; 2009 Jun 01; 132(Pt 6):1509-22. PubMed ID: 19416948
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
    Zheng R, Wang L, Fan J, Zhou Q.
    Cell Biol Int; 2009 Sep 01; 33(9):926-33. PubMed ID: 19524688
    [Abstract] [Full Text] [Related]

  • 15. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
    Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM.
    Clin Cancer Res; 2009 Nov 01; 15(21):6732-9. PubMed ID: 19843663
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro].
    Deng G, Yu JH, Ye ZQ, Hu ZQ.
    Zhonghua Nan Ke Xue; 2008 Feb 01; 14(2):116-21. PubMed ID: 18390174
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Change of vascular endothelial growth factor and its receptors expression in acute myeloid leukemia before and after treatment].
    Zhang JQ, Wang JK, Li YM.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb 01; 25(2):100-2. PubMed ID: 14990052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.